EMA Launches Pilot to Advance Non-Animal Testing Data

A structured pathway for regulators to evaluate New Approach Methodologies outside the marketing authorisation process is now open: EMA has launched a Voluntary Data Submission (VDS) pilot enabling companies, CROs, academic laboratories, and method developers to share NAM data directly with the European medicines regulatory network for scientific assessment.

The pilot addresses a persistent gap in non-clinical development strategy. Although NAMs, including organoids, microphysiological systems, and computational models, are increasingly deployed in early-stage research, data generated by these methods rarely reaches regulators. That absence limits the evidentiary base needed to formalise their acceptance under existing frameworks, including those aligned with ICH S-series guidelines and the 3Rs principles embedded in European medicines regulation.

Participation is non-binding and operates independently of any active marketing authorisation application. Applicants first submit an expression-of-interest form; selected organisations then provide a full briefing package for review by an operational expert group drawn from non-clinical specialists across the European network. Feedback is individual, non-binding, and non-decisional, meaning it carries no regulatory consequence for a product dossier, but does create a documented dialogue with assessors at an early stage.

For non-clinical leads and regulatory affairs teams, the practical value lies in that early engagement. Organisations that participate before the pilot closes in Q3 2027 will receive assessor-level feedback on methodology robustness and data interpretation, intelligence that can inform how NAM packages are positioned in future submissions. EMA has confirmed it will publish a lessons-learned report at the pilot's conclusion, which is expected to shape harmonised assessment approaches across member-state agencies.

CROs developing proprietary in vitro platforms or computational models have a parallel incentive: structured regulatory dialogue at this stage could accelerate the path toward formal guidance on NAM acceptance criteria, reducing the interpretive uncertainty that currently complicates non-clinical testing strategy decisions.

The lessons-learned report due after Q3 2027 will serve as the first consolidated regulatory signal on which NAM categories have accumulated sufficient evidentiary weight for integration into European non-clinical dossier requirements.

Source: European Medicines Agency (EMA) via ema.europa.eu, 1 September 2026.